0000000000087636

AUTHOR

Lourdes Florensa

0000-0001-5906-3311

showing 6 related works from this author

Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia.

2014

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell neoplasm characterized by overlapping myelodysplastic and myeloproliferative features. Diagnosis is based on persistent mo...

Cancer Researchmedicine.diagnostic_testChronic myelomonocytic leukemiaLeukemia Myelomonocytic ChronicTrisomyHematologyBiologyTrisomy 8medicine.diseaseClonal Hematopoietic Stem CellOncologyhemic and lymphatic diseasesmedicineCancer researchNeoplasmHumansDetection rateIn Situ Hybridization FluorescenceFluorescence in situ hybridizationChromosomes Human Pair 8Leukemialymphoma
researchProduct

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

2012

Summary Lenalidomide is an effective drug in low-risk myelodysplastic syndromes (MDS) with isolated del(5q), although not all patients respond. Studies have suggested a role for TP53 mutations and karyotype complexity in disease progression and outcome. In order to assess the impact of complex karyotypes on treatment response and disease progression in 52 lenalidomide-treated patients with del(5q) MDS, conventional G-banding cytogenetics (CC), single nucleotide polymorphism array (SNP-A), and genomic sequencing methods were used. SNP-A analysis (with control sample, lymphocytes CD3+, in 30 cases) revealed 5q losses in all cases. Other recurrent abnormalities were infrequent and were not ass…

OncologyMalemedicine.medical_specialtyMultivariate analysisCD3Single Nucleotide Polymorphism ArrayBiologyPolymorphism Single NucleotideInternal medicinemedicineHumansImmunologic FactorsPlateletLenalidomideIn Situ Hybridization FluorescenceLenalidomideAgedAged 80 and overMyelodysplastic syndromesCytogeneticsKaryotypeHematologyMiddle Agedmedicine.diseaseChromosome BandingThalidomideTreatment OutcomeMyelodysplastic SyndromesImmunologyMutationbiology.proteinDisease ProgressionChromosomes Human Pair 5FemaleChromosome Deletionmedicine.drugBritish journal of haematology
researchProduct

Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients

2010

Abstract Abstract 4113 Introduction: Most of the data related to RARS-T, a rare disorder, involve small cohorts of patients. We aimed to analyze more patients also considering a variety of myelodysplastic or myeloproliferative disorders. Objective: To compare a large cohort of patients with RARS-T to refractory anemia with ringed sideroblasts (RARS), refractory anemia with ringed sideroblasts and multilineage dysplasia (RARS-MD) or essential thrombocythemia (ET) at the time of diagnosis and during disease evolution, in terms of survival and complications. Materials: Data of a European multi-center study was used including 199 cases of RARS-T 173 cases of RARS, 102 cases of RARS-MD and 431 c…

Pediatricsmedicine.medical_specialtyThrombocytosisbusiness.industryEssential thrombocythemiaorganic chemicalsMyelodysplastic syndromesImmunologyCell BiologyHematologyRefractory anemia with ringed sideroblastsmedicine.diseaseBiochemistryGastroenterologybiological factorsbody regionsLeukemiaMyeloproliferative DisordersDysplasiaInternal medicineembryonic structuresmedicineHemoglobinbusinessneoplasmsBlood
researchProduct

Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes

2012

The reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is uncertain and its assessment was the major aim of this study. The different peripheral blood and bone marrow variables required for an adequate morphological classification were blindly evaluated by four cytomorphologists in samples from 50 patients with myelodysplastic syndromes. The degree of agreement among observers was calculated using intraclass correlation coefficient and the generalized kappa statistic for multiple raters. The degree of agreement for the percentages of blasts in bone marrow and peripheral blood, ring sideroblasts in bone marrow, and erythroid, granulocytic and m…

medicine.medical_specialtyPathologyHematologymedicine.diagnostic_testbusiness.industryMyelodysplastic syndromesHematologyErythroid dysplasiamedicine.diseaseGastroenterologyBone marrow examinationmedicine.anatomical_structureInternal medicineRefractory anemia with ring sideroblastsmedicineBone marrowRefractory anemia with excess of blastsbusinessErythroid Precursor Cells
researchProduct

Clinical Features And Course Of Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis

2012

Background Refractory anemia with ring sideroblasts associated with marked thrombocytosis was proposed as a provisional entity in the 2001 World Health Organization classification of myeloid neoplasms and also in the 2008 version, but its existence as a single entity is contested. We wish to define the clinical features of this rare myelodysplastic/myeloproliferative neoplasm and to compare its clinical outcome with that of refractory anemia with ring sideroblasts and essential thrombocythemia. Design and Methods We conducted a collaborative retrospective study across Europe. Our database included 200 patients diagnosed with refractory anemia with ring sideroblasts and marked thrombocytosis…

AdultBlood PlateletsMalemedicine.medical_specialtyAdolescentAnemiaAnèmiaRefractory anemia with ringed sideroblastsLower riskGastroenterologyRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHumansMyeloproliferative neoplasmSurvival analysisAgedRetrospective StudiesTumorsAged 80 and overThrombocytosisThrombocytosisPlatelet CountEssential thrombocythemiabusiness.industryAnemia RefractoryAnemiaHematologyJanus Kinase 2Middle Agedmedicine.diseaseSurvival AnalysisAnemia SideroblasticSurgeryEuropeRefractory anemia with ring sideroblastsMutationFemaleOriginal Articles and Brief ReportsbusinessThrombocythemia Essential
researchProduct

Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytoge…

2013

Cytogenetic aberrations identified by metaphase cytogenetics (MC) have diagnostic, prognostic, and therapeutic implications in myelodysplastic syndromes (MDS). However, in some MDS patients MC study is unsuccesful. Single nucleotide polymorphism array (SNP-A) based karyotyping could be helpful in these cases. We performed SNP-A in 62 samples from bone marrow or peripheral blood of primary MDS with an unsuccessful MC study. SNP-A analysis enabled the detection of aberrations in 31 (50%) patients. We used the copy number alteration information to apply the International Prognostic Scoring System (IPSS) and we observed differences in survival between the low/intermediate-1 and intermediate-2/h…

OncologyCancer Researchmedicine.medical_specialtyMyelodysplastic syndromesSingle Nucleotide Polymorphism ArrayCytogeneticsKaryotypeBiologymedicine.diseaseGene dosagemedicine.anatomical_structurePolymorphism (computer science)International Prognostic Scoring SystemInternal medicineGeneticsmedicineBone marrowGenes, Chromosomes and Cancer
researchProduct